Myocardial Infarction (MI) accounts for up to 60% of all cardiovascular morbidities and mortalities in the world. The pathophysiology of MI is complex, irreversible, and fatal. The USFDA has approved a beta-adrenergic receptor inhibitor for the treatment of MI. The FDA granted accelerated approval to metoprolol tartrate, a beta-adrenergic receptor inhibitor for the treatment of definite or suspected acute myocardial infarction. The drug was found to decrease cardiovascular mortality and approved for hemodynamically stable patients.
Metoprolol inhibits beta-2-adrenoreceptors, which are mainly located in the bronchial and vascular musculature and enable vasodilation. The approval of the drug was based on the positive results of a randomized clinical, double-blind, placebo-controlled clinical study. Around 1,395 patients were administered with metoprolol tartrate. The drug showed a…
